Charles River Laboratories International, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-1.5M | $-14.8M | $-276.6M | $54.4M | $52.3M | $25.5M | $-214.5M | $69.7M |
| Depreciation & Amortization | $67.3M | $67.2M | $78.3M | $85.2M | $119.5M | $120.4M | $102.1M | $88.2M |
| Depreciation | $39.3M | $41.3M | $45.1M | $44.8M | $44.3M | $43.4M | $48.4M | $48.5M |
| Amortization | $14.6M | $15.3M | $21.0M | $27.4M | $65.4M | $65.3M | $41.2M | $32.4M |
| Stock-Based Compensation | $19.8M | $22.4M | $17.6M | $23.3M | $17.0M | $13.1M | $17.2M | $19.3M |
| Net Cash from Operating Activities | $179.7M | $41.1M | $147.5M | $213.8M | $204.6M | $171.7M | $159.4M | $251.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $31.1M | $55.9M | $89.0M | $35.6M | $35.3M | $59.3M | $75.6M | $38.7M |
| Business Acquisitions | $62.2M | $405.0M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing Activities | $28.1M | $-407.8M | $-92.8M | $-33.7M | $-37.3M | $-45.5M | $-76.1M | $-21.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $115.6M | $208.3M | $96.0K | $93.0K | $7.4M | $353.1M | $124.0K | $100.8M |
| Net Cash from Financing Activities | $-164.7M | $347.7M | $-51.9M | $-152.6M | $-226.9M | $-105.3M | $-75.9M | $-207.5M |
| Net Change in Cash | $42.4M | $-17.8M | $6.8M | $24.5M | $-47.0M | $26.2M | $-6.1M | $30.6M |
| Free Cash Flow | $148.6M | $-14.8M | $58.6M | $178.2M | $169.3M | $112.4M | $83.7M | $213.1M |